vimarsana.com

Latest Breaking News On - Canada the co - Page 1 : vimarsana.com

Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal . Myovant Sciences, Inc.February 11, 2021 GMT ORGOVYX™ (relugolix) approved by the  U.S. Food and Drug Administration  (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in oncology and relugolix combination tablet in women’s health in the U.S. and Canada

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.